UBS Group Issues Pessimistic Forecast for Veeva Systems (NYSE:VEEV) Stock Price

Veeva Systems (NYSE:VEEV) had its price target lowered by equities research analysts at UBS Group from $220.00 to $190.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the technology company’s stock. UBS Group’s target price would indicate a potential upside of 4.59% from the stock’s current price.

A number of other brokerages have also issued reports on VEEV. Canaccord Genuity Group decreased their target price on shares of Veeva Systems from $280.00 to $235.00 and set a “hold” rating for the company in a research note on Thursday, March 5th. Stifel Nicolaus set a $230.00 price objective on Veeva Systems in a report on Thursday. Needham & Company LLC restated a “buy” rating and issued a $270.00 target price on shares of Veeva Systems in a research note on Thursday. BTIG Research reaffirmed a “buy” rating and issued a $340.00 target price on shares of Veeva Systems in a research report on Thursday. Finally, TD Cowen cut their price objective on Veeva Systems from $380.00 to $300.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Seventeen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $254.09.

Veeva Systems Stock Performance

Shares of NYSE:VEEV opened at $181.66 on Thursday. The company’s fifty day moving average is $166.29 and its two-hundred day moving average is $196.71. Veeva Systems has a 1-year low of $148.05 and a 1-year high of $310.50. The stock has a market capitalization of $29.67 billion, a price-to-earnings ratio of 33.48, a price-to-earnings-growth ratio of 0.81 and a beta of 0.95.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Wednesday, June 3rd. The technology company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. The firm had revenue of $882.95 million for the quarter, compared to analysts’ expectations of $857.73 million. Veeva Systems had a net margin of 28.44% and a return on equity of 13.80%. Veeva Systems’s revenue was up 16.3% on a year-over-year basis. During the same quarter last year, the company posted $1.97 earnings per share. Veeva Systems has set its FY 2027 guidance at 9.050-9.050 EPS and its Q2 2027 guidance at 2.210-2.220 EPS. Sell-side analysts expect that Veeva Systems will post 6.45 EPS for the current fiscal year.

Insider Buying and Selling at Veeva Systems

In other news, Director Priscilla Hung sold 750 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $155.64, for a total transaction of $116,730.00. Following the sale, the director directly owned 3,253 shares of the company’s stock, valued at $506,296.92. This represents a 18.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.60% of the company’s stock.

Institutional Investors Weigh In On Veeva Systems

Large investors have recently bought and sold shares of the company. Jensen Investment Management Inc. increased its position in shares of Veeva Systems by 1,924.5% during the third quarter. Jensen Investment Management Inc. now owns 413,213 shares of the technology company’s stock worth $123,100,000 after acquiring an additional 392,802 shares in the last quarter. Alphinity Investment Management Pty Ltd bought a new position in Veeva Systems during the 3rd quarter worth about $422,241,000. ABN AMRO Bank N.V. acquired a new stake in shares of Veeva Systems in the 3rd quarter valued at about $246,625,000. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Veeva Systems by 11.3% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 892,070 shares of the technology company’s stock valued at $199,137,000 after purchasing an additional 90,703 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S lifted its holdings in Veeva Systems by 293.4% during the 3rd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 26,979 shares of the technology company’s stock valued at $8,037,000 after purchasing an additional 20,121 shares during the last quarter. Institutional investors own 88.20% of the company’s stock.

Key Veeva Systems News

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva beat first-quarter estimates, posting adjusted EPS of $2.24 versus $2.14 expected and revenue of $882.9 million versus $857.7 million expected, with sales up 16.3% year over year. The company also said AI-related progress is helping drive the business. Article Title
• Positive Sentiment: Management issued upbeat guidance, including Q2 FY2027 EPS of $2.21 to $2.22 and revenue of $902 million to $905 million, both above Wall Street expectations. FY2027 EPS guidance was also above consensus, reinforcing confidence in continued growth. Article Title
• Positive Sentiment: Several analysts remained constructive after the earnings release: Needham reiterated a buy with a $270 target, BTIG kept a buy and lifted its target to $340, and Robert W. Baird raised its target to $260. Article Title
• Neutral Sentiment: Not all analyst updates were more bullish: Barclays and Piper Sandler both trimmed their price targets to $235, though each still kept an overweight rating, suggesting continued confidence despite slightly reduced expectations. Article Title

About Veeva Systems

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.